Varlitinib Ditosylate

N/A

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameVarlitinib Ditosylate
Drug Alias NameVarlitinibum伐利替尼威利替尼Varlitinib tosylateQBT-01 +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitorsReceptor protein-tyrosine kinase erbB-2 inhibitorsReceptor protein-tyrosine kinase erbB-4 inhibitors
TargetsEpidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-2Receptor protein-tyrosine kinase erbB-4
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursPancreatic Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSingapore +[19] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaDiscontinued
Originator CompaniesArray Biopharma
China Registration ClassN/A

Develop Information

Active CompaniesYonsei University
Inactive CompaniesCharles River Laboratories Contract Manufacturing Pa LlcArray BiopharmaAslan Pharmaceuticals Pte Ltd +[5] 
Active IndicationsStomach Neoplasms
Inactive IndicationsMetastatic breast cancerSolid tumoursPancreatic Neoplasms +[8] 

Other Information

ATC CodeN/A
Related LinksN/A